Madrigal Pharmaceuticals
Indianapolis, IN, USA
About Madrigal: Madrigal is a biopharmaceutical company pursuing novel therapeutics for non-alcoholic steatohepatitis (NASH), also known as metabolic dysfunction associated steatohepatitis (MASH). Our first therapy, Rezdiffra (resmetirom), was granted accelerated approval by the U.S. Food and Drug Administration (FDA) for the treatment of adults with NASH with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis) and is being studied in a Phase 3 trial for the treatment of NASH with compensated cirrhosis. Opportunity and Summary of Position: Access Reimbursement Manager The role of the Access Reimbursement Manager (ARM) is to minimize access and reimbursement barriers for patients and providers related to Resmetirom. They will accomplish this by executing the Patient Access strategic plan in a dedicated geographic area with physicians and institutional customers. The ARM will work closely with internal and external partners...